◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksB › BIM

bioMérieux S.A. (BIM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-08-16

bioMérieux S.A. (BIM) operates in the Diagnostics & Research industry and is headquartered in Marcy-l'Étoile, France with about 14,562 employees. Its market capitalization is roughly €9 billion. In the fiscal year ended 2025-12-31, BIM reported €4.1B in revenue and €398M in net income.

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments.

Interactive charts & full statements →

BIM Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue€4.1B€4.0B€3.7B€3.6B
Gross Profit€2.3B€2.2B€2.1B€2.0B
Operating Income (EBIT)€695M€638M€569M€626M
Net Income€398M€432M€358M€452M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIM Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid(€106M)(€100M)(€100M)(€101M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIM Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€5.6B€5.8B€5.3B€5.2B
Total Liabilities€1.5B€1.6B€1.5B€1.5B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIM viewer.

Other Companies in Diagnostics & Research

← BILSAll “B” companiesBINC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.